Finding 39934 (2022-001)

Material Weakness Repeat Finding
Requirement
M
Questioned Costs
-
Year
2022
Accepted
2023-09-28
Audit: 37679
Organization: The Rogosin Institute, Inc. (NY)
Auditor: Ernst & Young

AI Summary

  • Core Issue: Management needs to enhance subrecipient monitoring to comply with federal requirements, as previous policies were not fully effective.
  • Impacted Requirements: Subrecipients must be evaluated for compliance risks, including past audit results, as per 2 CFR section 200.332(b).
  • Recommended Follow-Up: Conduct annual reviews of subrecipient audit reports to assess compliance risks and improve monitoring practices.

Finding Text

Finding 2022-001 ? M. Subrecipient Monitoring Identification of the Federal Program: Grantor: Department of Health and Human Services Program Name: Research and Development Cluster Assistance Listing No. / FAIN: 93.847 / R24DK106743 Criteria or Specific Requirement: M. Subrecipient Monitoring ? A pass-through entity must evaluate each subrecipient?s risk of noncompliance for purposes of determining the appropriate subrecipient monitoring related to the subaward (2 CFR section 200.332(b)). Condition: Management should establish and implement a policy which addresses the requirement identified above, including evaluating the results of previous audits obtained by its subrecipients including whether or not the subrecipient receives a single audit in accordance with 2 CFR part 200, subpart F, and the extent to which the same or similar subaward has been audited as a major program. Cause: Management implemented updated policies related to subrecipient monitoring during 2022; however, such policies were not in effect for the full calendar year. Effect or Potential Effect: The lack of an effective control over subrecipient monitoring resulted in instances of noncompliance identified. Questioned Costs: Not applicable. Context: In a sample of two subrecipients within the Research and Development Cluster, two instances of noncompliance were identified where it could not be ascertained that the Institute verified that subrecipients have been audited as required by 2 CFR part 200, subpart F, as Institute management did not evaluate the subrecipients? compliance. Identification as a repeat finding: This finding was reported as finding 2021-001 in the prior year. Recommendation: Management has implemented a policy over subrecipient monitoring during 2022. Management should therefore perform an annual review of Uniform Guidance grant compliance audit reports of subrecipients on an annual basis to identify and evaluate the subrecipients? risk of noncompliance for purposes of determining the appropriate subrecipient monitoring. Views of Responsible Officials: Management concurs with this audit finding. During 2022, management implemented an annual review control whereby the reports will be reviewed to ensure compliance with federal agency requirements.

Corrective Action Plan

Finding 2022-001 ? M. Subrecipient Monitoring Information on the federal program: Grantor: Department of Health and Human Services Program Name: Research and Development Cluster Assistance Listing No. / FAIN: 93.847 / R24DK106743 Views of responsible officials and planned corrective actions: During 2022, management has implemented a policy which addresses the 2 CFR section 200.332(b) requirements, including evaluating the results of previous audits obtained by its subrecipients including whether or not the subrecipient receives a single audit in accordance and the extent to which the same or similar subaward has been audited as a major program. Name of responsible official: Name ? Betty-Jane Sloan Title ? Clinical Research Manager Phone: 646-317-0701 Email: bjsloan@nyp.org Projected completion date: June 10, 2022

Categories

Subrecipient Monitoring

Other Findings in this Audit

  • 39933 2022-002
    Significant Deficiency Repeat
  • 39935 2022-002
    Significant Deficiency Repeat
  • 39936 2022-002
    Significant Deficiency Repeat
  • 39937 2022-002
    Significant Deficiency Repeat
  • 39938 2022-002
    Significant Deficiency Repeat
  • 39939 2022-002
    Significant Deficiency Repeat
  • 39940 2022-002
    Significant Deficiency Repeat
  • 39941 2022-002
    Significant Deficiency Repeat
  • 39942 2022-002
    Significant Deficiency Repeat
  • 616375 2022-002
    Significant Deficiency Repeat
  • 616376 2022-001
    Material Weakness Repeat
  • 616377 2022-002
    Significant Deficiency Repeat
  • 616378 2022-002
    Significant Deficiency Repeat
  • 616379 2022-002
    Significant Deficiency Repeat
  • 616380 2022-002
    Significant Deficiency Repeat
  • 616381 2022-002
    Significant Deficiency Repeat
  • 616382 2022-002
    Significant Deficiency Repeat
  • 616383 2022-002
    Significant Deficiency Repeat
  • 616384 2022-002
    Significant Deficiency Repeat

Programs in Audit

ALN Program Name Expenditures
93.498 Provider Relief Fund and American Rescue Plan (arp) Rural Distribution $239,162
12.420 Military Medical Research and Development $75,897
93.847 Diabetes, Digestive, and Kidney Diseases Extramural Research $34,671
93.855 Allergy, Immunology and Transplantation Research $19,527